# US 2021/0230188 A1 · Crystal form of tri-cycle compound and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230188 A1
- Document ID: US20210230188A1
- Status: Published application
- Kind: A1
- Application number: 17/267,022
- Filed: 2019-08-23
- Published: 2021-07-29
- Earliest claimed: 2018-08-23
- Assignees: Fujian Cosunter Pharmaceutical Co., Ltd.
- Applicants: Fujian Cosunter Pharmaceutical Co., Ltd.
- Inventors: Jing WANG; Zhigan JIANG; Haiying HE; Yaxun YANG
- Web page: https://patentgrep.com/patent/US20210230188A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/20: for DNA viruses
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed are crystal form A and crystal form B of a compound represented by formula (I), and application thereof in the preparation of medicaments for treating HBV-related diseases.

## Claims

### Claim 1

A crystal form A of a compound represented by formula (I) having an X-ray powder diffraction (XRPD) pattern comprising characteristic diffraction peaks with the following angles of 2θ: 5.56±0.2°, 15.56±0.2° and 16.17±0.2°,

### Claim 2 (depends on 1)

The crystal form A of claim 1, wherein the X-ray powder diffraction pattern comprises characteristic diffraction peaks with the following angles of 2θ: 5.56±0.2°, 10.84±0.2°, 15.56±0.2°, 16.17±0.2°, 22.14±0.2°, 22.70±0.2°, 27.76±0.2° and 28.44±0.2°.

### Claim 3 (depends on 2)

The crystal form A of claim 2, wherein the XRPD pattern is shown in FIG. 1.

### Claim 4 (depends on 1)

The crystal form A of claim 1 exhibiting an endothermic peak with an onset of 229.95° C. as measured by differential scanning calorimetry curve (DSC).

### Claim 5 (depends on 4)

The crystal form A of claim 4, wherein the DSC is shown in FIG. 2.

### Claim 6 (depends on 1)

The crystal form A of claim 1 having a thermogravimetric analysis (TGA) curve with a weight loss of 0.3382% at 62±3° C. and a weight loss of 0.8753% at 230±3° C.

### Claim 7 (depends on 6)

The crystal form A of claim 6, wherein the TGA is shown in FIG. 3.

### Claim 8

A crystal form B of a compound represented by formula (I) having an X-ray powder diffraction pattern comprising characteristic diffraction peaks with the following angles of 2θ: 12.70±0.2°, 15.64±0.2° and 23.03±0.2°,

### Claim 9 (depends on 8)

The crystal form B of claim 8, wherein the X-ray powder diffraction pattern comprises characteristic diffraction peaks with the following angles of 2θ: 9.56±0.2°, 12.70±0.2°, 14.41±0.2°, 15.64±0.2°, 19.70±0.2°, 23.03±0.2°, 23.98±0.2° and 27.65±0.2°.

### Claim 10 (depends on 9)

The crystal form B of claim 9, wherein the XRPD pattern is shown in FIG. 4.

### Claim 11 (depends on 8)

The crystal form B of claim 8 exhibiting an endothermic peak with an onset of 233.59° C. as measured by differential scanning calorimetry curve.

### Claim 12 (depends on 11)

The crystal form B of claim 11, wherein the DSC is shown in FIG. 5.

### Claim 13 (depends on 8)

The crystal form B of claim 8 having a thermogravimetric analysis curve with a weight loss of 0.04890% at 120±3° C.

### Claim 14 (depends on 13)

The crystal form B of claim 13, wherein the TGA is shown in FIG. 6.

### Claim 15 (depends on 1)

A method for treating HBV-related diseases in a subject in need thereof, comprising administering an effective amount of the crystal form A of claim 1 to the subject.

### Claim 16 (depends on 8)

A method for treating HBV-related diseases in a subject in need thereof, comprising administering an effective amount of the crystal form B of claim 8 to the subject.
